Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2028

Pages: 160 Published: February 28, 2020 Report Code: GDHC191PIDR

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • Listen
    iSpeech

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, making up 90–95% of all kidney cancer cases. Globally, RCC represents the sixth most frequently diagnosed cancer in men and 10th in women. RCC consists of a heterogeneous group of tumors with distinct genetic and metabolic defects. The major histologic RCC subtype is ccRCC, which represents 80–95% of cases (as shown in Table 2). Other forms of the disease, usually referred as non-clear cell RCC (nccRCC), include papillary RCC (PRCC), chromophobe RCC (ChRCC), translocation carcinoma, medullary carcinoma, and collecting duct carcinoma. At present, metastatic RCC (mRCC) is considered incurable, with only a small minority of patients achieving a complete response (CR) to treatment. However, major advances in the treatment landscape within the past 15 years have significantly improved progression-free survival (PFS) and overall survival (OS).

GlobalData is expecting a total of 7 new entrants to launch over the forecast period in the 8MM from 2018–2028 while specific marketed agents are expected to undergo label expansion. The competition will be particularly fierce in renal cell carcinoma, immune checkpoint inhibitors and combinations thereof competing for market share in the adjuvant setting and in fist-line treatment of metastatic RCC. No drugs are currently in late development for nccRCC leaving the treatment of that population an unmet need within the forecast period.

KEY QUESTIONS ANSWERED

Seven late-stage pipeline agents are going to enter the renal cell carcinoma market from 2018 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?

What are the current unmet needs in renal cell carcinoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?

What is the market outlook in the 8MM from 2018-2028? Consideration of major patent expiries, launch of new premium priced agents and expected label expansions.

What are the main corporate trends? Who are the current and future players?

Scope

Overview of renal cell carcinoma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline renal cell carcinoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting renal cell carcinoma therapeutics sales in the 8MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global renal cell carcinoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The main drivers of growth include the anticipated approval and launch of 7 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.

The main barriers to growth in the 8MM include the patent expiry of major brands and the short sales opportunity window due to the aggressiveness of the disease.

Among the late-stage pipeline products and marketed agents, TKI inhibitors and immune checkpoint inhibitors are expected to generate the greatest revenues over the forecast period.

The two most important unmet needs in the renal cell carcinoma market include: improved treatments that increase complete response rates and treatment options for refractory patients.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global renal cell carcinoma therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global renal cell carcinoma market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the renal cell carcinoma therapeutics market from 2018-2028.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Key Players

Altor Biosciences

Aveo Pharma

Bayer

Calithera Biosciences

Xynomic Pharmaceuticals

 Eisai

 Merck kGaA

AstraZeneca

Betta Pharmaceuticals

Bristol-Myers-Squibb

Exelixis

Merck & Co.

Nektar Therapeutics

Novartis

Pfizer

Roche

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Renal Cell Carcinoma: Executive Summary

2.1 The RCC market is expected to grow to $6.4B in 2028

2.2 The Development of Combination Treatments Is the Pillar of Corporate Strategies in RCC

2.3 Opportunities Remain for More Effective Therapies and Treatments for nccRCC

2.4 The RCC Pipeline Is Diverse, Comprising Label Expansions and Novel Mechanisms of Action

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Prognostic models

4.3 Biomarkers

4.4 Clinical Staging

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods, Population

5.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC

5.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Stage at Diagnosis

5.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Prognostic Model

5.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Biomarkers

5.4.7 Forecast Assumptions and Methods, Five-Year and 10-Year Diagnosed Prevalent Cases of RCC

5.5 Epidemiological Forecast for RCC (2018–2028)

5.5.1 Diagnosed Incident Cases of RCC

5.5.2 Age-Specific Diagnosed Incident Cases of RCC

5.5.3 Sex-Specific Diagnosed Incident Cases of RCC

5.5.4 Diagnosed Incident Cases of RCC by Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of RCC Stage IV by Prognostic Model

5.5.6 Diagnosed Incident Cases of RCC Stage IV by Biomarkers

5.5.7 Five-Year Diagnosed Prevalent Cases of RCC

5.5.8 10-Year Diagnosed Prevalent Cases of RCC

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Available Treatments

6.2 US

6.2.1 Diagnosis

6.2.2 Clinical Practice

6.3 5EU

6.3.1 Diagnosis

6.3.2 Clinical Practice

6.4 Japan

6.4.1 Diagnosis

6.4.2 Clinical Practice

6.5 China

6.5.1 Diagnosis

6.5.2 Clinical Practice

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Improved Treatments that Increase Complete Response Rates in mRCC Patients

8.3 Treatment Options for Refractory Patients

8.4 Treatment of nccRCC

8.5 Effective Adjuvant Therapies

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.2.1 Immunotherapies

10.2.2 Combination treatments

10.2.3 Targeting Earlier Stages of the Disease

10.3 Pfizer’s Portfolio Assessment

10.4 Merck & Co.’s Portfolio Assessment

10.5 Bristol-Myers Squibb’s Portfolio Assessment

10.6 Exelixis’ Portfolio Assessment

10.7 Eisai’s Portfolio Assessment

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic/Biosimilar Erosion

12.3.9 Pricing and clinical positioning of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of Tables

Table 1: RCC: Key Metrics in the 8MM

Table 2: Classifications of RCC

Table 3: TNM and Staging Classification System for RCC

Table 4: Risk Factors and Comorbidities for RCC

Table 5: RCC Clinical Stages at Diagnosis

Table 6: Treatment Guidelines for RCC

Table 7: Country Profile – US

Table 8: Country Profile – 5EU

Table 9: Country Profile – Japan

Table 10: Leading Treatments for Disease RCC, 2019

Table 11: Pfizer’s RCC Portfolio Assessment, 2019

Table 12: Merck & Co.’s RCC Portfolio Assessment, 2019

Table 13: BMS’s RCC Portfolio Assessment, 2019

Table 14: Exelixis’ RCC Portfolio Assessment, 2019

Table 15: Eisai’s RCC Portfolio Assessment, 2019

Table 16: RCC Market – Global Drivers and Barriers, 2018–2028

Table 17: Key Events Impacting Sales for RCC in the US, 2018–2028

Table 18: RCC Market – Drivers and Barriers in the US, 2018–2028

Table 19: Key Events Impacting Sales for RCC in the 5EU, 2018–2028

Table 20: RCC Market – Drivers and Barriers in the 5EU, 2018–2028

Table 21: Key Events Impacting Sales for RCC in Japan, 2018–2028

Table 22: RCC Market – Global Drivers and Barriers in Japan, 2018–2028

Table 23: Key Events Impacting Sales for RCC in China, 2018–2028

Table 24: RCC Market – Global Drivers and Barriers in China, 2018–2028

Table 25: Key Historical and Projected Launch Dates for RCC

Table 26: Key Historical and Projected Patent Expiry Dates for RCC

Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for RCC in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in RCC During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of RCC During the Forecast Period

Figure 4: Key pathways and drug targets in RCC.

Figure 5: 8MM, Diagnosed Incidence of RCC, Men, Ages ≥18 Years, 2008–2028

Figure 6: 8MM, Diagnosed Incidence of RCC, Women, Ages ≥18 Years, 2008–2028

Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of RCC

Figure 8: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Stage at Diagnosis

Figure 9: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Prognostic Model

Figure 10: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of EGFR)

Figure 11: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of VEGF)

Figure 12: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of mTOR)

Figure 13: 8MM, Sources Used, Five-Year and 10-Year Diagnosed Prevalent Cases of RCC

Figure 14: 8MM, Diagnosed Incident Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018

Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2018

Figure 16: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥18 Years, N, 2018

Figure 17: 8MM, Diagnosed Incident Cases of RCC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2018

Figure 18: 8MM, Diagnosed Incident Cases of RCC Stage IV by Prognostic Model, Ages ≥18 Years, Both Sexes, N, 2018

Figure 19: 8MM, Diagnosed Incident Cases of RCC Stage IV by Biomarkers, Ages ≥18 Years, Both Sexes, N, 2018

Figure 20: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018

Figure 21: 8MM, 10-Year Diagnosed Prevalent Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018

Figure 22: Treatment Algorithm for advanced/metastatic RCC

Figure 23: Unmet Needs and Opportunities in RCC

Figure 24: Overview of the Development Pipeline in RCC, 2019

Figure 25: Pivotal Phase II/III Trials for the Promising RCC Pipeline Agents, 2019

Figure 26: Competitive Assessment of the Late-Stage Pipeline Agents for RCC, 2018–2028

Figure 27: Analysis of the Company Portfolio Gap in RCC During the Forecast Period

Figure 28: Global (8MM) Sales Forecast by Country for RCC in 2018 and 2028

Figure 29: Sales Forecast by Class for RCC in the US in 2018 and 2028

Figure 30: Sales Forecast by Class for RCC in the 5EU in 2018 and 2028

Figure 31: Sales Forecast by Class for RCC in Japan in 2018 and 2028

Figure 32: Sales Forecast by Class for RCC in China in 2018 and 2028

$10995

Can be used by individual purchaser only

$32985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.